Sanofi's Praluent Closes Gap On Amgen's Repatha In Europe
This article was originally published in Scrip
Executive Summary
With its formal EU approval now announced, Sanofi SA and Regeneron Pharmaceuticals Inc.'s powerful cholesterol-lowering drug Praluent (alirocumab) will now catch up with its key competitor there, Amgen's Repatha (evolocumab), but their high price tags will probably mean a slow up-take for both therapies in the region.